Scientists have discovered that the absence of a specific protein in cells lining the esophagus may cause inflammation and tissue damage in people with eosinophilic esophagitis (EoE). EoE affects as many as 150,000 people in the United States, many of whom are children. People with EoE experience difficult or painful swallowing, vomiting and nutritional problems because an accumulation of immune cells called eosinophils scars the esophagus.
Food Allergy News Releases
Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.
While rare, some people experience recurrent episodes of anaphylaxis—a life-threatening allergic reaction that causes symptoms such as the constriction of airways and a dangerous drop in blood pressure—for which the triggers are never identified. Recently, researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, found that some patients’ seemingly inexplicable anaphylaxis was actually caused by an uncommon allergy to a molecule found naturally in red meat.
The National Institutes of Health intends to award $42.7 million over seven years to the Consortium of Food Allergy Research (CoFAR) so it may continue evaluating new approaches to treat food allergy. Established in 2005, the CoFAR has been continuously funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. The first year of funding has been awarded, and awards will be made in subsequent years based on the availability of funds.
An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines today to aid health care providers in early introduction of peanut-containing foods to infants to prevent the development of peanut allergy.
A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results from an ongoing clinical trial. The treatment, called epicutaneous immunotherapy or EPIT, was safe and well-tolerated, and nearly all participants used the skin patch daily as directed.
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating small, gradually increasing amounts of peanut protein daily.
Introducing peanut-containing foods during infancy as a peanut allergy prevention strategy does not compromise the duration of breastfeeding or affect children’s growth and nutritional intakes, new findings show. The work, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is published online on June 10 in the Journal of Allergy and Clinical Immunology.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is seeking public comment on a draft update to the 2010 Guidelines for the Diagnosis and Management of Food Allergy in the United States (link is external) to address the prevention of peanut allergy.
The benefits of regularly consuming peanut-containing foods early in life to prevent the development of peanut allergy persist even after stopping peanut consumption for one year, new clinical trial findings show.
Oral immunotherapy for peanut allergy induces early, distinct changes in immune T-cell populations that potentially may help researchers determine which people will respond well to the therapy and which immune mechanisms are involved in the response, a new study suggests.